 | • レポートコード：MRC2208A0174 • 出版社/出版日：Transparency Market Research / 2022年6月 • レポート形態：英文、PDF、135ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査資料では、アメリカのダーマルフィラー（皮膚充填剤）市場について広く調査・分析を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、製品別分析、原料別分析、用途別分析、エンドユーザー別分析、競争状況などをまとめました。なお、当書に掲載されている企業情報には、AbbVie、Advanced Aesthetic Technologies、Anika Therapeutics, Inc.、BioPlus Co., Ltd.、Croma-Pharma GmbH、Cytophil, Inc.、DR. Korman Laboratories、Galderma、Huons USA、Merz Pharma GmbH & Co. KGaA、Revance、Sinclair Pharmaなどが含まれています。 |
U.S. Dermal Filler Market – Scope of Report
TMR’s report on the dermal filler market in U.S. studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the dermal filler market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of dermal filler market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the dermal filler market in U.S..
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the dermal filler market in U.S..
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the dermal filler market in U.S.. These serve as valuable tools for existing market players as well as for entities interested in participating in the dermal filler market in U.S..
The report delves into the competitive landscape of the dermal filler market. Key players operating in the dermal filler market in U.S. have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the dermal filler market profiled in this report.
Research Methodology
The research methodology is a combination of exhaustive primary and secondary research to analyze the dermal filler market.
Secondary Research
Secondary research included a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we referred to include, but are not limited to:
Company websites, presentations, annual reports, white papers, technical papers, product brochures
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
Veterinary Council of U.S.
U.S.n Federation of Animal Health
Animal Welfare Board of U.S.
Company Information
Statista
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of the research, we conducted in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents the bulk of research efforts, supplemented by extensive secondary research.
We conducted primary interviews with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who took part in the process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts
Key opinion leaders specializing in the market with respect to different industry verticals
Primary participants included, but are not limited to:
Bayer AG
Elanco Products Company
Merck & Co., Inc.
Ceva Sante Animale
Virbac SA
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter
Market Estimation: Market size estimations involved an in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we used modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Population, inflation rates, and others
Industry Indicators: Production data, R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived by taking into account drivers, restraints/challenges, opportunities prevailing in the market, and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise consumption data are the other pivotal factors considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: U.S. Dermal Fillers Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. U.S. Dermal Fillers Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. Regulatory Scenario in the U.S.
5.3. Licensing Agreement Analysis
5.4. COVID-19 Impact Analysis
6. U.S. Dermal Fillers Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Biodegradable
6.3.2. Non-biodegradable
6.4. Market Attractiveness Analysis, by Product
7. U.S. Dermal Fillers Market Analysis and Forecast, by Material
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Material, 2017–2031
7.3.1. Calcium Hydroxylapatite
7.3.2. Hyaluronic Acid
7.3.3. Collagen
7.3.4. Poly-L-Lactic Acid
7.3.5. Polymethylmethacrylate (PMMA)
7.3.6. Fat
7.3.7. Others
7.4. Market Attractiveness Analysis, by Material
8. U.S. Dermal Fillers Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Facial Line Correction Treatment
8.3.2. Lip Enhancement
8.3.3. Scar Treatment
8.3.4. Others
8.4. Market Attractiveness Analysis, by Application
9. U.S. Dermal Fillers Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Dermatology Clinics
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user
10. Competition Landscape
10.1. Market Player – Competition Matrix (by tier and size of companies)
10.2. Market Share Analysis, by Company, 2020
10.3. Company Profiles
10.3.1. AbbVie
10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.1.2. Product Portfolio
10.3.1.3. SWOT Analysis
10.3.1.4. Strategic Overview
10.3.2. Advanced Aesthetic Technologies, Inc.
10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.2.2. Product Portfolio
10.3.2.3. SWOT Analysis
10.3.2.4. Strategic Overview
10.3.3. Anika Therapeutics, Inc.
10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.3.2. Product Portfolio
10.3.3.3. SWOT Analysis
10.3.3.4. Strategic Overview
10.3.4. BioPlus Co., Ltd.
10.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.4.2. Product Portfolio
10.3.4.3. SWOT Analysis
10.3.4.4. Strategic Overview
10.3.5. Croma-Pharma GmbH
10.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.5.2. Product Portfolio
10.3.5.3. SWOT Analysis
10.3.5.4. Strategic Overview
10.3.6. Cytophil, Inc.
10.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.6.2. Product Portfolio
10.3.6.3. SWOT Analysis
10.3.6.4. Strategic Overview
10.3.7. DR. Korman Laboratories.
10.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.7.2. Product Portfolio
10.3.7.3. SWOT Analysis
10.3.7.4. Strategic Overview
10.3.8. Galderma
10.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.8.2. Product Portfolio
10.3.8.3. SWOT Analysis
10.3.8.4. Strategic Overview
10.3.9. Huons USA
10.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.9.2. Product Portfolio
10.3.9.3. SWOT Analysis
10.3.9.4. Strategic Overview
10.3.10. Merz Pharma GmbH & Co. KGaA
10.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.10.2. Product Portfolio
10.3.10.3. SWOT Analysis
10.3.10.4. Strategic Overview
10.3.11. Revance
10.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.11.2. Product Portfolio
10.3.11.3. SWOT Analysis
10.3.11.4. Strategic Overview
10.3.12. Sinclair Pharma
10.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.12.2. Product Portfolio
10.3.12.3. SWOT Analysis
10.3.12.4. Strategic Overview
10.3.13. Suneva Medical, Inc.
10.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.13.2. Product Portfolio
10.3.13.3. SWOT Analysis
10.3.13.4. Strategic Overview
10.3.14. Syneron Medical Ltd.
10.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.14.2. Product Portfolio
10.3.14.3. SWOT Analysis
10.3.14.4. Strategic Overview
10.3.15. TEOXANE Laboratories
10.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
10.3.15.2. Product Portfolio
10.3.15.3. SWOT Analysis
10.3.15.4. Strategic Overview
Table 01: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by Product, 2017–2031
Table 02: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by Material, 2017–2031
Table 03: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 04: U.S. Dermal Filler Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031